King Pharmaceuticals offers new dosage strengths of Avinza to provide more treatment options for people with chronic pain

New Capsule Strengths Provide Greater Dosing Flexibility

BRISTOL, Tenn. -- King Pharmaceuticals, Inc. (NYSE: KG) today announced the launch of two new FDA-approved dosage strengths for AVINZA® (morphine sulfate extended-release capsules). The new dosing strengths, 45mg and 75mg, complement the currently available 30mg, 60mg, 90mg and 120mg dosages. AVINZA® is a long-acting opioid for patients with moderate to severe chronic pain who require around-the-clock pain relief for an extended period of time.

AVINZA® was approved in 2002 and is prescribed by healthcare professionals for a wide range of patients including those with osteoarthritis, low-back pain, cancer pain, and chronic noncancer pain. “These new capsule strengths provide physicians with additional options that may enable more customized approaches to treating people with chronic pain,” said Dr Eric Carter, Chief Science Officer of King.


AVINZA® is an extended-release opioid agent for patients requiring continuous, around-the-clock analgesia for an extended period of time. AVINZA® is appropriate for chronic, moderate to severe pain associated with malignant and nonmalignant pain conditions. AVINZA® is an extended-release form of morphine allowing for once-daily dosing. AVINZA® is covered by a formulation patent that extends through November 2017. Because AVINZA® is an extended-release product, it should not be chewed, crushed, or dissolved due to the risk of rapid release and absorption of a potentially fatal dose of morphine. AVINZA® should not be taken with alcohol or drug products containing alcohol. AVINZA® is NOT intended for use as a prn analgesic and it is not indicated for postoperative use. The most common serious adverse events reported with administration of AVINZA® are vomiting, nausea, death (in patients treated for pain in underlying malignancy), dehydration, dyspnea, and sepsis. Additional common adverse events reported during clinical studies include constipation, somnolence, and headache. AVINZA® is contraindicated in patients with known hypersensitivity to morphine, morphine salts, or any components of the product.

About King Pharmaceuticals, Inc.

King, headquartered in Bristol, Tennessee,is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in-licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products and technologies that complement the Company’s focus in specialty-driven markets, particularly neuroscience and hospital. King is also a leader in the development, registration, manufacture and marketing of pharmaceutical products for food producing animals.

SOURCE: King Pharmaceuticals, Inc.

To read more Press Release articles, click here.